EXEL Shares Outstanding History
Below is a table of the EXEL shares outstanding history going back to 3/5/2010:

Date EXEL Shares Outstanding
3/5/2010107.99M
5/5/2010108.58M
7/30/2010108.66M
10/29/2010108.98M
2/15/2011109.49M
4/28/2011127.84M
7/29/2011128.97M
10/21/2011129.69M
2/15/2012148.42M
4/27/2012148.48M
7/27/2012148.88M
11/2/2012183.60M
2/14/2013183.72M
4/30/2013183.80M
7/29/2013184.12M
10/25/2013184.20M
2/19/2014194.61M
4/24/2014194.69M
7/24/2014195.11M
10/29/2014195.22M
2/26/2015195.90M
4/23/2015196.03M
8/3/2015225.43M
10/29/2015227.22M
2/19/2016228.19M
4/28/2016228.74M
7/28/2016230.33M
10/26/2016286.46M
2/16/2017290.87M
4/24/2017292.51M
7/26/2017293.90M
10/24/2017295.85M
2/12/2018296.31M
4/23/2018296.87M
7/24/2018298.04M
10/22/2018298.98M
2/12/2019300.13M
4/22/2019301.77M
7/22/2019302.91M
10/21/2019303.85M
2/18/2020305.39M
4/27/2020306.66M
7/27/2020309.00M
10/26/2020310.24M
2/1/2021311.99M
4/26/2021313.39M
7/26/2021315.05M

Also see: EXEL Market Cap History
EXEL YTD Return
EXEL Historical Shares Outstanding:
+9.85% CAGR
EXEL Historical Shares Outstanding: +9.85% CAGR

Mouse over chart for data details
3/5/2010 ...7/26/2021
Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved for renal cell carcinoma and previously treated hepatocellular carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), which is an inhibitor of MEK approved as part of a combination regimen to treat melanoma; and MINNEBRO® (esaxerenone), which is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension. We show 47 historical shares outstanding datapoints in our coverage of EXEL's shares outstanding history.

Understanding the changing numbers of EXEL shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EXEL versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EXEL by allowing them to research EXEL shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree EXEL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Exelixis (EXEL) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

EYE Shares Outstanding History
EYEG Shares Outstanding History
EYEN Shares Outstanding History
EYES Shares Outstanding History
EYPT Shares Outstanding History
FATE Shares Outstanding History
FBIO Shares Outstanding History
FBRX Shares Outstanding History
FCRE Shares Outstanding History
FCSC Shares Outstanding History
More Healthcare companies »

 

EXEL Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.